Veradermics Cash Flow Statement
NYSE: MANEHealthcareBiotechnologyUSD
130.90+4.27 (+3.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veradermics free cash flow
In fiscal 2025, Veradermics generated -$71.6 million of operating cash flow and spent $24,000 on capital expenditures. That left free cash flow of -$71.6 million.
Summary generated from market data by MetaCap's automated system. Methodology
Veradermics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Net Income | -70.00M | -26.49M |
| Net Income growth (YoY) | — | — |
| Stock-Based Compensation | 1.44M | 250.00K |
| Change in Working Capital | -8.40M | -539.00K |
| Operating Cash Flow | -71.60M | -23.69M |
| Capital Expenditures | -24.00K | 0 |
| Investing Cash Flow | -118.86M | 0 |
| Financing Cash Flow | 159.14M | 60.48M |
| Net Change in Cash | -31.32M | 36.79M |
| Free Cash Flow | -71.63M | -23.69M |
This table shows 2 annual periods of Veradermics's cash flow statement, from FY 2025 back to FY 2024, across 9 line items including net income, stock-based compensation, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow MANE's reporting calendar. What is a cash flow statement?